Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus
暂无分享,去创建一个
Robert A Greevy | Xulei Liu | A. Hung | H. Murff | T. Elasy | C. Roumie | Xulei Liu | Carlos G. Grijalva | M. Griffin | R. Greevy | Marie R Griffin | Christianne L Roumie | Carlos G Grijalva | Adriana M Hung | Harvey J Murff | Tom A Elasy
[1] A. Hung,et al. Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year , 2012, Pharmacoepidemiology and Drug Safety.
[2] A. Hung,et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function , 2012, Kidney international.
[3] D. Mozaffarian,et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.
[4] D. Mozaffarian,et al. Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.
[5] Medicaid Services,et al. International Classification of Diseases, Ninth Revision, Clinical Modification , 2011 .
[6] Nisa M. Maruthur,et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations , 2011, Annals of Internal Medicine.
[7] A. Hung,et al. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort , 2011, Pharmacoepidemiology and drug safety.
[8] Executive Summary: Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.
[9] G. Corrao,et al. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy , 2011, European Journal of Clinical Pharmacology.
[10] John B. Carlin,et al. Bias and efficiency of multiple imputation compared with complete‐case analysis for missing covariate values , 2010, Statistics in medicine.
[11] A. Mackinnon,et al. The use and reporting of multiple imputation in medical research – a review , 2010, Journal of internal medicine.
[12] A. Hung,et al. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a veterans administration retrospective cohort study , 2010, Pharmacoepidemiology and drug safety.
[13] John B Carlin,et al. American Journal of Epidemiology Practice of Epidemiology Strategies for Multiple Imputation in Longitudinal Studies , 2022 .
[14] S. Nissen,et al. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. , 2010, Archives of internal medicine.
[15] Craig I Coleman,et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. , 2010, JAMA.
[16] B. Wells,et al. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy , 2010, Diabetes Care.
[17] P. Elliott,et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database , 2009, BMJ : British Medical Journal.
[18] P. Gideon,et al. An algorithm to identify incident myocardial infarction using Medicaid data , 2009, Pharmacoepidemiology and drug safety.
[19] R. Stafford,et al. National trends in treatment of type 2 diabetes mellitus, 1994-2007. , 2008, Archives of internal medicine.
[20] Renee F Wilson,et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. , 2008, Archives of internal medicine.
[21] Jordi Castellsague,et al. Validation of ICD‐9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data , 2008, Pharmacoepidemiology and drug safety.
[22] Shari Bolen,et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus , 2007, Annals of Internal Medicine.
[23] A. Lincoff,et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.
[24] Changing Incident Diabetes Regimens , 2007, Diabetes Care.
[25] C. Koro,et al. Coronary heart disease outcomes in patients receiving antidiabetic agents , 2007, Pharmacoepidemiology and drug safety.
[26] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[27] F. Weaver,et al. Veterans’ Access to and Use of Medicare and Veterans Affairs Health Care , 2007, Medical care.
[28] S. Normand,et al. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database , 1999, Journal of General Internal Medicine.
[29] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.
[30] M. Cheang,et al. Validity of a Prescription Claims Database to Estimate Medication Adherence in Older Persons , 2006, Medical care.
[31] S. Schneeweiss. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.
[32] D. Cryer,et al. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. , 2005, Diabetes care.
[33] Sebastian Schneeweiss,et al. Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using External Information: The Example of COX2 Inhibitors and Myocardial Infarction , 2005, Epidemiology.
[34] A. Folsom,et al. Trends in the sensitivity, positive predictive value, false-positive rate, and comparability ratio of hospital discharge diagnosis codes for acute myocardial infarction in four US communities, 1987-2000. , 2004, American journal of epidemiology.
[35] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[36] Lori S. Parsons. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques , 2001 .
[37] D. Rubin,et al. Estimating and Using Propensity Scores with Partially Missing Data , 2000 .
[38] Yang C. Yuan,et al. Multiple Imputation for Missing Data: Concepts and New Development , 2000 .
[39] B. Psaty,et al. Assessment and Control for Confounding by Indication in Observational Studies , 1999, Journal of the American Geriatrics Society.
[40] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[41] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[42] R. Kronmal,et al. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. , 1998, Biometrics.
[43] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[44] L. J. Wei,et al. The Robust Inference for the Cox Proportional Hazards Model , 1989 .
[45] V. Basevi. Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.
[46] T. Schacker,et al. Annals of Internal Medicine , 1992 .
[47] G. Knatterud,et al. The UGDP and Insulin Therapy: A Reply , 1979, Diabetes Care.
[48] N. Freinkel,et al. The UGDP Controversy , 1979, Diabetes.
[49] M. P. Stern,et al. Zespół metaboliczny jako czynnik prognostyczny ułatwiający rozpoznanie osób z ryzykiem rozwoju cukrzycy typu 2 i/lub chorób układu sercowo-naczyniowego , 1979 .
[50] P. Forsham,et al. "Settling the UGDP controversy"? , 1975, JAMA.
[51] S. Schor. Editorials: Statistical problems in clinical trials: the UGDP study revisited. , 1973, The American journal of medicine.
[52] C. Meinert,et al. The UGDP Controversy: Clinical Trials Versus Clinical Impressions , 1972, Diabetes.
[53] H. Seltzer. A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (UGDP) , 1972, Diabetes.
[54] G. Knatterud,et al. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. , 1971, JAMA.
[55] C. Meinert,et al. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. IV. A preliminary report on phenoformin results. , 1971, JAMA.